|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Changes in hippocampal connectivity in the early stages of Alzheimer's disease: evidence from resting state fMRI显示文摘 | Wang L Zang Y He Y Liang M Zhang X Tian L Wu T Jiang T Li K | 2006 | 中国生物学文摘2006，20，10： | 84 |
| 2 | Current concepts on osteonecrosis of the femoral head显示文摘It is estimated that 20000 to 30000 new patients are diagnosed with osteonecrosis annually accounting for approximately 10% of the 250000 total hip arthroplasties done annually in the United States. Thelack of level 1 evidence in the literature makes it difficult to identify optimal treatment protocols to manage patients with pre-collapse avascular necrosis of the femoral head, and early intervention prior to collapse is critical to successful outcomes in joint preserving procedures. There have been a variety of traumatic and atraumatic factors that have been identified as risk factors for osteonecrosis, but the etiology and pathogenesis still remains unclear. Current osteonecrosis diagnosis is dependent upon plain anteroposterior and frog-leg lateral radiographs of the hip, followed by magnetic resonance imaging(MRI). Generally, the first radiographic changes seen by radiograph will be cystic and sclerotic changes in the femoral head. Although the diagnosis may be made by radiograph, plain radiographs are generally insufficient for early diagnosis, therefore MRI is considered the most accurate benchmark. Treatment options include pharmacologic agents such as bisphosphonates and statins, biophysical treatments, as well as joint-preserving and joint-replacing surgeries. the surgical treatment of osteonecrosis of the femoral head can be divided into two major branches: femoral head sparing procedures(FHSP) and femoral head replacement procedures(FHRP). In general, FHSP are indicated at pre-collapse stages with minimal symptoms whereas FHRP are preferred at post-collapse symptomatic stages. It is difficult to know whether any treatment modality changes the natural history of core decompression since the true natural history of core decompression has not been delineated. | Joaquin Moya-Angeler Arianna L Gianakos Jordan C Villa Amelia Ni Joseph M Lane | 2015 | World Journal of Orthopedics2015，6，8： | 94 |
| 3 | 新辅助免疫治疗可以为MMR表达以及MMR缺失型早期结肠癌患者带来病理缓解显示文摘PD-1联合CTLA-4阻滞剂对晚期错配修复蛋白(MMR)缺失(dMMR)型结直肠癌患者的治疗非常有效,但对MMR表达(pMMR)的患者无效。我们假设在早期结肠癌患者中新辅助免疫疗法具有更好的疗效。在探索性NICHE研究中(Clinical Trials.gov:NCT03026140),dMMR或pMMR患者在手术前接受单剂量伊匹单抗(ipilimumab)和两剂量纳武单抗(nivolumab)治疗,pMMR患者联合或者不联合使用塞来昔布。本研究的主要观察指标是安全性和可行性。在纳入分析的40例患者中,包括21例dMMR患者和19例pMMR患者,他们均接受了治疗,其中3例经安全性讨论后仅接受了纳武单抗单药治疗。患者治疗耐受性良好,所有患者均接受了根治性切除且未延期进行,符合主要观察指标的观察预期。在接受伊匹单抗+纳武单抗治疗的患者(20例dMMR患者和15例pMMR患者)中,共35例可进行疗效和转化效果评估。在20例dMMR患者中,病理缓解率为100%(95%CI:86%~100%),有19例患者达到主要病理缓解(MPRs,残留存活肿瘤≤10%),其中包括12例患者达到完全病理缓解。在15例pMMR患者中,有4例达到病理缓解,其中包括3例主要病理缓解和1例部分缓解。CD8+PD-1+T细胞浸润情况可预测pMMR患者的治疗应答。基于这些数据认为,如果新辅助免疫治疗效果能被基于至少3年无病生存数据的更加大型的临床研究结果支持,那么其则有望作为特定结肠癌患者的标准治疗方案。 | 张荣欣 CHALABI M FANCHI L F DIJKSTRA K K | 2020 | 结直肠肛门外科2020，26，6： | 87 |
| 4 | 青藏高原东缘龙门山晚新生代走滑挤压作用的沉积响应显示文摘成都盆地位于青藏高原东缘,夹于龙门山与龙泉山之间,盆地的长轴方向平行于龙门山,呈现为北东—南西向展布的线性盆地。盆地中充填了3.6Ma以来的半固结—松散堆积物,最大厚度为541m,在垂向上由下部的大邑砾岩、中部的雅安砾石层和上部的上更新统至全新统砾石层组成,其与下覆地层均为不整合接触,显示该盆地是一个单独的成盆期,并非是在中生代前陆盆地基础上形成的继承性盆地。在垂直于龙门山造山带方向上,成都盆地具不对称的楔形结构,沉积基底面整体向西呈阶梯状倾斜,盆地中充填的碎屑物质均来源于盆地西侧的龙门山,具横向水系和单向充填的特征;而且盆地的沉降中心具有逐渐向远离造山带方向迁移的特征,显示盆地的挤压方向垂直于龙门山主断裂,造成了成都盆地在垂直于造山带方向上的构造缩短。在平行于龙门山造山带方向上,成都盆地具有一系列的北东向延伸的次级凸起和凹陷,凹陷和凸起相间分布,且在空间上呈斜列形式展布于盆地的底部,其中次级凹陷(沉降中心)和冲积扇具有向平行龙门山造山带方向迁移的特征,表明成都盆地西缘的龙门山断裂具有右旋走滑的特征。鉴于以上特征,认为成都盆地是在龙门山造山带晚新生代走滑与逆冲的联合作用下形成的走滑挤压盆地。 | 李勇 周荣军 Densmore A L Ellis M A 黎兵 | 2006 | 沉积学报2006，24，2： | 65 |
| 5 | 烟碱向降烟碱转化对烟叶麦斯明和TSNA含量的影响显示文摘以白肋烟TN90为材料,研究了非转化株、低转化株及高转化株烟叶样品的烟碱转化程度及降烟碱含量与烟叶麦斯明和烟草特有亚硝胺(TSNA)含量的关系。结果表明,随着烟株烟碱转化能力的提高和烟叶降烟碱含量的增加,叶片和主脉的麦斯明含量呈线性增加。当烟碱转化率超过20%时,麦斯明含量超过了假木贼碱的含量。在4种主要的TSNA中,具有不同烟碱转化能力的样品间4-(甲基亚硝胺基)-1-(3-吡啶基)-1-丁酮(NNK)、N-亚硝基新烟草碱(NAT)和N-亚硝基假木贼碱(NAB)含量没有显著差异,N-亚硝基降烟碱(NNN)含量则随着烟碱转化能力的提高和降烟碱含量的增加而大幅度升高,尤其在主脉中表现更为明显。NNN占总TSNA的比例随烟碱转化程度的提高而增加,在高转化烟株中可高达90%,其它3种TSNA占总TSNA的比例相应降低。叶片中NAT含量和比例一般高于NNK,而在主脉中NNK含量高于NAT。 | 史宏志 Bush L P Krauss M | 2004 | 烟草科技2004，37，10： | 55 |
| 6 | Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: A meta-analysis显示文摘AIM: To determine the clinical impact of portal vein thrombosis in terms of both mortality and hepatic decompensations(variceal hemorrhage, ascites, portosystemic encephalopathy) in adult patients with cirrhosis.METHODS: We identified original articles reported through February 2015 in MEDLINE, Scopus, Science Citation Index, AMED, the Cochrane Library, and relevant examples available in the grey literature. Two independent reviewers screened all citations for inclusion criteria and extracted summary data. Random effects odds ratios were calculated to obtain aggregate estimates of effect size across included studies, with 95%CI.RESULTS: A total of 226 citations were identified and reviewed, and 3 studies with 2436 participants were included in the meta-analysis of summary effect. Patients with portal vein thrombosis had an increased risk of mortality(OR = 1.62, 95%CI: 1.11-2.36, P = 0.01). Portal vein thrombosis was associated with an increased risk of ascites(OR = 2.52, 95%CI: 1.63-3.89, P < 0.001). There was insufficient data available to determine the pooled effect on other markers of decompensation including gastroesophageal variceal bleeding or hepatic encephalopathy. CONCLUSION: Portal vein thrombosis appears to increase mortality and ascites, however, the relatively small number of included studies limits more generalizable conclusions. More trials with a direct comparison group are needed. | Jonathan G Stine Puja M Shah Scott L Cornella Sean R Rudnick Marwan S Ghabril George J Stukenborg Patrick G Northup | 2015 | World Journal of Hepatology2015，7，27： | 42 |
| 7 | 龙门山断裂带走滑方向的反转及其沉积与地貌标志显示文摘根据龙门山前陆盆地西缘沉降中心、冲积扇侧向迁移、活动构造地貌和古地磁等标志及龙门山在中生代以来的走滑作用和走滑方向的标定研究,结果表明:龙门山断裂带具有走滑性质,走滑方向曾发生过反转,在反转之前以左行走滑作用为特征,在反转之后以右行走滑作用为特征。根据地层记录和古地磁证据,认为龙门山走滑方向反转的时间应介于43 M a^3.6 M a之间,即由中生代至早新生代时期的左行走滑作用反转为晚新生代时期的右行走滑作用。然对龙门山断裂带走滑方向反转的成因初步分析认为晚新生代龙门山右行走滑作用是印-亚碰撞后构造作用的产物,晚三叠世至早新生代左行走滑作用是青藏高原自晚三叠世以来大陆碰撞作用导致松潘-甘孜褶皱带北东-南西向缩短的产物。 | 李勇 周荣军 A L Densmore M A Ellis | 2006 | 矿物岩石2006，26，4： | 32 |
| 8 | 帕博利珠单抗治疗伴脑转移NSCLC患者的一项非随机、开放Ⅱ期试验的长期随访结果和生物标志物分析显示文摘背景与目的我们开展了一项帕博利珠单抗用于伴未治疗脑转移的非小细胞肺癌(non-small cell lung cancer,NSCLC)或黑色素瘤患者的疗效和安全性的II期试验,旨在评估程序性死亡受体1(programmed cell death 1,PD-1)抑制剂在中枢神经系统(central nervous system,CNS)中的疗效。中期结果已发表,现报道对NSCLC队列的更新分析结果。方法这是一项开放性、单中心、II期试验。纳入标准:年龄≥18岁,诊断为晚期NSCLC并伴有≥1个5 mm-20 mm脑转移病灶,既往从未治疗或之前放疗后进展,无神经系统症状,不需要激素治疗且美国东部肿瘤协作组(Eastern Cooperative Oncology Group,ECOG)<2分。患者每2周接受一次帕博利珠单抗(10 mg/kg)治疗。队列1为程序性死亡配体1(programmed cell death ligand 1,PD-L1)≥1%的患者,队列2为PD-L1<1%或未评估的患者。主要终点是脑转移患者缓解比例。所有经治患者均纳入疗效与安全性终点的分析。该研究已结束入组,并于Clinicaltrials.gov登记注册,注册号为NCT02085070。结果2014年3月31日-2018年5月21日,共42例患者接受治疗。中位随访时间为8.3个月(IQR:4.5个月-26.2个月)。队列1的37例患者中11例有脑转移缓解[29.7%(95%CI:15.9%-47.0%)]。队列2未观察到缓解。治疗相关的3级-4级不良事件(adverse events,AEs)包括2例肺炎、1例全身症状、1例结肠炎、1例肾上腺皮质功能不全、1例高血糖症和1例低钾血症。6例(14%)患者发生了治疗相关的严重不良事件,包括肺炎、急性肾损伤、低钾血症和肾上腺皮质功能不全。没有观察到治疗相关死亡病例。结论帕博利珠单抗治疗PD-L1≥1%的NSCLC伴脑转移患者有效,且对所有纳入的未经治疗的脑转移患者安全。需要进一步探索免疫治疗用于NSCLC合并CNS转移。 | Sarah B GOLDBERG Kurt A SCHALPER Scott N GETTINGER Amit MAHAJAN Roy S HERBST Anne C CHANG Rogerio LILENBAUM Frederick H WILSON Sacit Bulent OMAY James B YU Lucia JILAVEANU Thuy TRAN Kira PAVLIK Elin ROWEN Heather GERRSH Annette KOMLO Richa GUPTA Hailey WYATT Matthew RIBEIRO Yuval KLUGER Geyu ZHOU Wei WEI Veronica L CHANG Harriet M KLUGER 董晓荣(翻译/校对) | 2021 | 中国肺癌杂志2021，24，9： | 34 |
| 9 | 最新AD研究用诊断标准:IWG-2标准显示文摘在过去的8年中,国际工作组织(IWG)和美国国立老化研究院-阿尔茨海默协会(NIA-AA)建立了阿尔茨海默病(AD)诊断标准,它能更好地定义AD的临床表型,整合了生物标记物于诊断流程中,并覆盖了疾病的全程。本意见书充分地权衡了IWG标准的优缺点,建议改进诊断框架。依据这些改进,AD的诊断变得简单,只要有恰当的AD临床表型(典型或不典型)和与AD的病理相一致的病理生理学生物标志物出现。我们认为疾病的下游的定位性生物标志,如容积性磁共振成像(MRI)和氟脱氧葡萄糖-正电子发射型计算机断层成像(FDG-PET)等,适合更好地测量和监测疾病过程。本文还详述了非典型性AD、混合性AD和AD临床前期的特异诊断标准。 | 陈刚 曹雯炜 俞羚 糜建华 Dubois B Feldman HH Jacova C Hampel H Molinuevo JL Blennow K DeK osky ST Gauthier S Selkoe D Bateman R Cappa S Crutch S Engelborghs S Frisoni GB Fox NC Galasko D Habert MO Jicha GA Nordberg A Pasquier F Rabinovici G Robert P Rowe C Salloway S Sarazin M Epelbaum S de Souza LC Vellas B Visser PJ Schneider L Stern Y Scheltens P Cummings JL | 2014 | 神经病学与神经康复学杂志2014，11，3： | 31 |
| 10 | Cellular and molecular aspects of gastric cancer显示文摘胃的癌症与变的负担仍然是一个全球杀手从发展了到发展中的世界。癌症沿着被定义由的一个多级式的过程发展不同组织学并且 pathophysiological 阶段。几基因、渐成说的改变调停从一个的转变上演到另外一个,这些在 oncogenes 包括变化,瘤压制或基因和房间骑车并且错配修理基因。在对胃的癌症的战斗的最重要的进展为这癌症作为最重要的获得的病因论的代理人与 Helicobacter pylori (H pylori ) 的角色的识别来了。最近的工作在阐明上集中了位于肿瘤的过程下面的复杂 host/microbial 相互作用。现在进这癌症的致病和阻止并且根除的前景有可观的卓见疾病成为了现实。也许更重要地, H 导致 pylori 的胃的致癌作用的学习为理解更复杂的人的癌症提供一个范例。在这评论,我们检验位于 H 下面的分子、细胞的事件导致 pylori 的胃的癌症。 | Malcolm G Smith Georgina L Hold Eiichi Tahara Emad M El-Omar | 2006 | World Journal of Gastroenterology2006，12，19： | 29 |
| 11 | 尿钠排泄、血压、心血管病与死亡率的关系:社区前瞻性流行病学队列研究显示文摘WHO建议人群钠摄人<2 g/d作为预防心血管病的措施之一,但这一目标在任何国家都没有实现。该建议主要基于短期血压试验的个体水平数据,没有来自随机试验或观察性研究的关于低钠摄入与降低心血管事件的数据。前瞻性城市农村流行病学研究目前正在21个国家进行。该文对其中18个国家的数据进行分析,其中包含了临床结果数据。 | Mente A O'Donnell M Rangarajan S McQueen M Dagenais G Wielgosz A Lear S Ah STL Wei L Diaz R Avezum A Lopez-Jaramillo P Lanas F Mony P Szuba A Iqbal R Yusuf R Mohammadifard N Khatib R Yusoff K Ismail N Gulec S Rosengren A Yusufali A Kruger L Tsolekile LP Chifamba J Dans A Alhabib KF Yeates K Teo K Yusuf S 刘莉 叶鹏 | 2018 | 中华高血压杂志2018，26，12： | 29 |
| 12 | 急性缺血性卒中的血管内治疗:神经介入外科学学会实践标准委员会的报告显示文摘目的总结采用血管内技术治疗急性缺血性卒中的有关证据并等级分类。方法对美国心脏协会(American Heart Association,AHA)以前发表的推荐意见进行审查并作为当前流程的基础。在此这基础上,进行系统的文献回顾以评估支持急性缺血性卒中血管内治疗的证据。根据AHA卒中委员会和牛津大学循证医学中心提出的循证医学证据分级指南进行评估。对操作安全性、技术效果以及对临床转归的影响进行特别审核。 | K A Blackham P M Meyers T A Abruzzo F C Alberquerque D Fiorella J Fraser D Frei C D Gandhi D V Heck J A Hirsch D P Hsu M Jayaraman S Narayanan C Prestigiacomo J L Sunshine 包元飞(译) 李永坤(译) 刘新峰(译) | 2012 | 国际脑血管病杂志2012，20，12： | 28 |
| 13 | 血管内超声去肾交感神经术治疗高血压:一项多中心,国际,单盲,随机,假手术对照试验显示文摘早期研究表明,基于射频的去肾交感神经术可降低中度高血压患者的血压。研究者研究了在没有使用抗高血压药物的情况下,使用血管内超声去。肾交感神经术是否会降低高血压患者的动态血压。 | 刘青 叶鹏 Azizi M Schmieder RE Mahfoud F Weber MA Daemen J Davies J Basile J Kirtane AJ Wang Y Lobo MD Saxena M Feyz L Rader F Lurz P Sayer J Sapoval M Levy T Sanghvi K Abraham J Sharp ASP Fisher NDL Bloch MJ Reeve-Stoffer H Coleman L Mullin C Mauri L | 2018 | 中华高血压杂志2018，26，10： | 27 |
| 14 | Magnetic resonance imaging in breast cancer:A literature review and future perspectives显示文摘Early detection and diagnosis of breast cancer are essential for successful treatment. Currently mammography and ultrasound are the basic imaging techniques for the detection and localization of breast tumors. The low sensitivity and specificity of these imaging tools resulted in a demand for new imaging modalities and breast magnetic resonance imaging(MRI) has become increasingly important in the detection and delineation of breast cancer in daily practice. However, the clinical benefits of the use of pre-operative MRI in women with newly diagnosed breast cancer is still a matter of debate. The main additional diagnostic value of MRI relies on specific situations such as detecting multifocal, multicentric or contralateral disease unrecognized on conventional assessment(particularly in patients diagnosed with invasive lobular carcinoma), assessing the response to neoadjuvant chemotherapy, detection of cancer in dense breast tissue, recognition of an occult primary breast cancer in patients presenting with cancer metastasis in axillary lymph nodes, among others. Nevertheless, the development of new MRI technolo-gies such as diffusion-weighted imaging, proton spectroscopy and higher field strength 7.0 T imaging offer a new perspective in providing additional information in breast abnormalities. We conducted an expert literature review on the value of breast MRI in diagnosing and staging breast cancer, as well as the future potentials of new MRI technologies. | Gisela LG Menezes Floor M Knuttel Bertine L Stehouwer Ruud M Pijnappel Maurice AAJ van den Bosch | 2014 | World Journal of Clinical Oncology2014，5，2： | 25 |
| 15 | Langerin在Langerhans细胞组织细胞增生症和非Langerhans细胞组织细胞性疾病中的表达显示文摘 | Lan S K Chu P G Weiss L M 黄文斌(摘译) | 2008 | 临床与实验病理学杂志2008，24，5： | 23 |
| 16 | 血管周围脂肪组织中的Bmal1通过血管紧张素原转录调控管理静息期血压显示文摘血管周围脂肪组织(perivascular adipose tissue,PVAT)围绕血管,构成了在生理条件下保持血管张力所需的脉管系统的独特的功能整体层。然而,关于PVAT与血压调节之间的关系的资料很少,包括其对昼夜血压变化的潜在作用。 | Chang L Xiong W Zhao X Fan Y Guo Y Garcia-Barrio M Zhang J Jiang Z Lin JD Chen YE 刘青 叶鹏 | 2018 | 中华高血压杂志2018，26，2： | 23 |
| 17 | 青藏高原东缘龙门山晚新生代剥蚀厚度与弹性挠曲模拟显示文摘龙门山是青藏高原东缘边界山脉,具有青藏高原地貌、龙门山高山地貌和山前冲积平原三个一级地貌单元。利用数字高程模式图像和裂变径迹年代测定方法研究和计算龙门山晚新生代剥蚀厚度与剥蚀速率,结果表明:3.6 Ma以来龙门山的剥蚀厚度介于1.91-2.16 km之间,剥蚀速率介于0.53-0.60 mm/a之间。在此基础上,开展了该地区岩石圈的弹性挠曲模拟,结果表明龙门山的隆升机制具有以构造缩短隆升和剥蚀卸载隆升相叠合的特点。3.6 Ma之前,龙门山的隆升与逆冲推覆构造负载有关,以构造缩短驱动的构造隆升为特色;3.6 Ma之后,龙门山的隆升与剥蚀卸载驱动的抬升有关,并以剥蚀卸载隆升为特色,进而提出了龙门山晚新生代以来的隆升机制以剥蚀成山作用为主的认识。 | 李勇 A L DENSMORE 周荣军 M A ELLIS | 2005 | 地质学报2005，79，5： | 21 |
| 18 | 脑缺氧是影响严重颅脑创伤患者短期预后的独立危险因素(英文)显示文摘Background:Brain hypoxia(BH)can aggravate outcome after severe traumatic brain injury(TBI).Whether BH or reduced brain oxygen(Pbto2)is an independent outcome predictor or a marker of disease severity is not fully elucidated.Objective To analyze the relationship between Pbto2,intracranial pressure(ICP),and cerebral perfusion pressure(CPP)and to examine whether BH correlates with worse outcome independently of ICP and CPP.Methods We studied103patients | Oddo M Levine JM Mackenzie L Frangos S Feihl F Kasner SE Katsnelson M Pukenas B Macmurtrie E Maloney-Wilensky E Kofke WA Leroux PD | 2011 | 中华神经外科疾病研究杂志2011，10，5： | 21 |
| 19 | Golgi protein-73:A biomarker for assessing cirrhosis and prognosis of liver disease patients显示文摘BACKGROUND Reliable biomarkers of cirrhosis,hepatocellular carcinoma(HCC),or progression of chronic liver diseases are missing.In this context,Golgi protein-73(GP73)also called Golgi phosphoprotein-2,was originally defined as a resident Golgi type II transmembrane protein expressed in epithelial cells.As a result,GP73 expression was found primarily in biliary epithelial cells,with only slight detection in hepatocytes.However,in patients with acute or chronic liver diseases and especially in HCC,the expression of GP73 is significantly up-regulated in hepatocytes.So far,few studies have assessed GP73 as a diagnostic or prognostic marker of liver fibrosis and disease progression.AIM To assess serum GP73 efficacy as a diagnostic marker of cirrhosis and/or HCC or as predictor of liver disease progression.METHODS GP73 serum levels were retrospectively determined by a novel GP73 ELISA(QUANTA Lite®GP73,Inova Diagnostics,Inc.,Research Use Only)in a large cohort of 632 consecutive patients with chronic viral and non-viral liver diseases collected from two tertiary Academic centers in Larissa,Greece(n=366)and Debrecen,Hungary(n=266).Aspartate aminotransferase(AST)/Platelets(PLT)ratio index(APRI)was also calculated at the relevant time points in all patients.Two hundred and three patients had chronic hepatitis B,183 chronic hepatitis C,198 alcoholic liver disease,28 autoimmune cholestatic liver diseases,15 autoimmune hepatitis,and 5 with other liver-related disorders.The duration of follow-up was 50(57)mo[median(interquartile range)].The development of cirrhosis,liver decompensation and/or HCC during follow-up were assessed according to internationally accepted guidelines.In particular,the surveillance for the development of HCC was performed regularly with ultrasound imaging and alpha-fetoprotein(AFP)determination every 6 mo in cirrhotic and every 12 mo in non-cirrhotic patients.RESULTS Increased serum levels of GP73(>20 units)were detected at initial evaluation in 277 out of 632 patients(43.8%).GP73-seropositivity correlated at baseline with the presence of cirrhosis(96.4%vs 51.5%,P<0.001),decompensation of cirrhosis(60.3%vs 35.5%,P<0.001),presence of HCC(18.4%vs 7.9%,P<0.001)and advanced HCC stage(52.9%vs 14.8%,P=0.002).GP73 had higher diagnostic accuracy for the presence of cirrhosis compared to APRI score[Area under the curve(AUC)(95%CI):0.909(0.885-0.934)vs 0.849(0.813-0.886),P=0.003].Combination of GP73 with APRI improved further the accuracy(AUC:0.925)compared to GP73(AUC:0.909,P=0.005)or APRI alone(AUC:0.849,P<0.001).GP73 levels were significantly higher in HCC patients compared to non-HCC[22.5(29.2)vs 16(20.3)units,P<0.001)and positively associated with BCLC stage[stage 0:13.9(10.8);stage A:17.1(16.8);stage B:19.6(22.3);stage C:32.2(30.8);stage D:45.3(86.6)units,P<0.001]and tumor dimensions[very early:13.9(10.8);intermediate:19.6(18.4);advanced:29.1(33.6)units,P=0.004].However,the discriminative ability for HCC diagnosis was relatively low[AUC(95%CI):0.623(0.570-0.675)].Kaplan-Meier analysis showed that the detection of GP73 in patients with compensated cirrhosis at baseline,was prognostic of higher rates of decompensation(P=0.036),HCC development(P=0.08),and liver-related deaths(P<0.001)during follow-up.CONCLUSION GP73 alone appears efficient for detecting cirrhosis and superior to APRI determination.In combination with APRI,its diagnostic performance can be further improved.Most importantly,the simple GP73 measurement proved promising for predicting a worse outcome of patients with both viral and nonviral chronic liver diseases. | Nikolaos K Gatselis Tamás Tornai Zakera Shums Kalliopi Zachou Asterios Saitis Stella Gabeta Roger Albesa Gary L Norman Mária Papp George N Dalekos | 2020 | World Journal of Gastroenterology2020，26，34： | 21 |
| 20 | Role of the gut microbiota in inflammatory bowel disease pathogenesis: What have we learnt in the past 10 years?显示文摘Our understanding of the microbial involvement in inflammatory bowel disease(IBD) pathogenesis has increased exponentially over the past decade. The development of newer molecular tools for the global assessment of the gut microbiome and the identification of nucleotide-binding oligomerization domain-containing protein 2 in 2001 and other susceptibility genes for Crohn's disease in particular has led to better understanding of the aetiopathogenesis of IBD. The microbial studies have elaborated the normal composition of the gut microbiome and its perturbations in the setting of IBD. This altered microbiome or 'dysbiosis' is a key player in the protracted course of inflammation in IBD. Numerous genome-wide association studies have identified further genes involved in gastrointestinal innate immunity(including polymorphisms in genes involved in autophagy: ATG16L1 and IGRM), which have helped elucidate the relationship of the local innate immunity with the adjacent luminal bacteria. These developments have also spurred the search for specific pathogens which may have a role in the metamorphosis of the gut microbiome from a symbiotic entity to a putative pathogenic one. Here we review advances in our understanding of microbial involvement in IBD pathogenesis over the past 10 years and offer insight into how this will shape our therapeutic management of the disease in the coming years. | Georgina L Hold Megan Smith Charlie Grange Euan Robert Watt Emad M El-Omar Indrani Mukhopadhya | 2014 | World Journal of Gastroenterology2014，20，5： | 21 |
您所在的机构暂未开通此部分的功能，请联系管理员